SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed hiv-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen

  • R. Campo
  • , E. Dejesus
  • , U. F. Bredeek
  • , K. Henry
  • , H. Khanlou
  • , K. Logue
  • , C. Brinson
  • , P. Benson
  • , L. Dau
  • , H. Wang
  • , K. White
  • , J. Flaherty
  • , T. Fralich
  • , B. Guyer
  • , D. Piontkowsky

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Fingerprint

Dive into the research topics of 'SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed hiv-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry

Neuroscience